Denver, CONCT04192344Now EnrollingIRB Ready

Neoplasms Clinical Trial in Denver, CO

Access cutting-edge neoplasms treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Abbisko Therapeutics Co, Ltd

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms treatment provided free

Apply for This Denver Location

Check if you qualify for this neoplasms clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Neoplasms Study in Denver

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

Sponsor: Abbisko Therapeutics Co, Ltd

Who Can Participate

Inclusion Criteria

Histologically confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
ECOG (electrocorticogram) performance status 0\~1
Life expectancy ≥ 3 months
Adequate organ function and bone marrow function For patients with tenosynovial giant cell tumor (TGCT) :
A diagnosis of TGCT \[i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist, and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;

Exclusion Criteria

Known allergy or hypersensitivity to any component of the investigational drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
Known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study treatment
Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with the exception of alopecia and vitiligo
Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
Concomitant use of strong inhibitors or inducers of CYP3A4
Active central nervous system (CNS) metastases
Impaired cardiac function or clinically significant cardiac disease
Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection
Refractory/uncontrolled ascites or pleural effusion
Pregnant or nursing For patients with tenosynovial giant cell tumor (TGCT) :
Known allergy or hypersensitivity to any component of the investigational drug product
For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US）

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT04192344) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms Treatment Options in Denver, CO

If you're searching for neoplasms treatment options in Denver, CO, this clinical trial (NCT04192344) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Denver, CO

See all myeloproliferative neoplasms clinical trials recruiting in Denver — not just this study.

Browse Myeloproliferative Neoplasms Trials in Denver →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO